Updated treatment strategies for intestinal behçet’s disease

Yong Eun Park, JaeHee Cheon

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Behçet’s disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. In particular, gastrointestinal involvement in BD is followed by severe complications, including massive bleeding, bowel perforation, and fistula, which can lead to significant morbidity and mortality. However, the management of intestinal BD has not yet been properly established. Intestinal BD patients with a severe clinical course experience frequent disease aggravations and often require recurrent corticosteroid and/or immunomodulatory therapies, or even surgery. However, a considerable number of patients with intestinal BD are often refractory to conventional therapies such as corticosteroids and immunomodulators. Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor α are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD.

Original languageEnglish
Pages (from-to)1-19
Number of pages19
JournalKorean Journal of Internal Medicine
Volume33
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Intestinal Diseases
Biological Products
Vascular Skin Diseases
Adrenal Cortex Hormones
Oral Ulcer
Therapeutics
Immunomodulation
Eye Diseases
Immune System Diseases
Immunologic Factors
Protein Transport
Ulcer
Fistula
Tumor Necrosis Factor-alpha
Hemorrhage
Morbidity
Mortality

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

@article{58d4a62359ea4cddb8d947476760ff9c,
title = "Updated treatment strategies for intestinal beh{\cc}et’s disease",
abstract = "Beh{\cc}et’s disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. In particular, gastrointestinal involvement in BD is followed by severe complications, including massive bleeding, bowel perforation, and fistula, which can lead to significant morbidity and mortality. However, the management of intestinal BD has not yet been properly established. Intestinal BD patients with a severe clinical course experience frequent disease aggravations and often require recurrent corticosteroid and/or immunomodulatory therapies, or even surgery. However, a considerable number of patients with intestinal BD are often refractory to conventional therapies such as corticosteroids and immunomodulators. Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor α are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD.",
author = "Park, {Yong Eun} and JaeHee Cheon",
year = "2018",
month = "1",
day = "1",
doi = "10.3904/kjim.2017.377",
language = "English",
volume = "33",
pages = "1--19",
journal = "Korean Journal of Internal Medicine",
issn = "1226-3303",
publisher = "Korean Association of Internal Medicine",
number = "1",

}

Updated treatment strategies for intestinal behçet’s disease. / Park, Yong Eun; Cheon, JaeHee.

In: Korean Journal of Internal Medicine, Vol. 33, No. 1, 01.01.2018, p. 1-19.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Updated treatment strategies for intestinal behçet’s disease

AU - Park, Yong Eun

AU - Cheon, JaeHee

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Behçet’s disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. In particular, gastrointestinal involvement in BD is followed by severe complications, including massive bleeding, bowel perforation, and fistula, which can lead to significant morbidity and mortality. However, the management of intestinal BD has not yet been properly established. Intestinal BD patients with a severe clinical course experience frequent disease aggravations and often require recurrent corticosteroid and/or immunomodulatory therapies, or even surgery. However, a considerable number of patients with intestinal BD are often refractory to conventional therapies such as corticosteroids and immunomodulators. Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor α are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD.

AB - Behçet’s disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. In particular, gastrointestinal involvement in BD is followed by severe complications, including massive bleeding, bowel perforation, and fistula, which can lead to significant morbidity and mortality. However, the management of intestinal BD has not yet been properly established. Intestinal BD patients with a severe clinical course experience frequent disease aggravations and often require recurrent corticosteroid and/or immunomodulatory therapies, or even surgery. However, a considerable number of patients with intestinal BD are often refractory to conventional therapies such as corticosteroids and immunomodulators. Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor α are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD.

UR - http://www.scopus.com/inward/record.url?scp=85040909056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040909056&partnerID=8YFLogxK

U2 - 10.3904/kjim.2017.377

DO - 10.3904/kjim.2017.377

M3 - Review article

VL - 33

SP - 1

EP - 19

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 1226-3303

IS - 1

ER -